[
  {
    "ts": null,
    "headline": "Alvotech: Why FDA Delays Don't Break The Bull Case",
    "summary": "Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. See why ALVO stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=37cb85cba880bde7dbd1e2759d21fcf2c7efcf23e1ff29fe3d128d489296803e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769031286,
      "headline": "Alvotech: Why FDA Delays Don't Break The Bull Case",
      "id": 138200440,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159194981/image_2159194981.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. See why ALVO stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=37cb85cba880bde7dbd1e2759d21fcf2c7efcf23e1ff29fe3d128d489296803e"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate",
    "summary": "Eli Lilly wins FDA Breakthrough Therapy status for sofetabart mipitecan in certain patients with platinum-resistant ovarian cancer.",
    "url": "https://finnhub.io/api/news?id=103c45e18deac07844851b1ebdbd5acccd9e3427805dc8db902c8902f578bce8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769009460,
      "headline": "FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate",
      "id": 138197142,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Eli Lilly wins FDA Breakthrough Therapy status for sofetabart mipitecan in certain patients with platinum-resistant ovarian cancer.",
      "url": "https://finnhub.io/api/news?id=103c45e18deac07844851b1ebdbd5acccd9e3427805dc8db902c8902f578bce8"
    }
  },
  {
    "ts": null,
    "headline": "Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon",
    "summary": "Corvus Pharmaceuticals, Inc. shares are up on solid soquelitinib AD phase 1 data: 75% hit EASI 75 at 200 mg BID, many benefits, broad upside. Click for this CRVS update.",
    "url": "https://finnhub.io/api/news?id=e0cb69eae9c335eddda1ee9277683030abe30f4247fc28d9b0dae6a71bd4b1f0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769007039,
      "headline": "Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon",
      "id": 138198106,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242759989/image_2242759989.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Corvus Pharmaceuticals, Inc. shares are up on solid soquelitinib AD phase 1 data: 75% hit EASI 75 at 200 mg BID, many benefits, broad upside. Click for this CRVS update.",
      "url": "https://finnhub.io/api/news?id=e0cb69eae9c335eddda1ee9277683030abe30f4247fc28d9b0dae6a71bd4b1f0"
    }
  },
  {
    "ts": null,
    "headline": "Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference",
    "summary": "SAN DIEGO, January 21, 2026--Biocom today announced a distinguished keynote session for its 2026 Global Partnering & Investor Conference, taking place February 24 to 26 at The Lodge at Torrey Pines in La Jolla, California.",
    "url": "https://finnhub.io/api/news?id=7ded13c7bffe9a1eb7f0ee157151db09457910563196ab72f67489c6c0cd22d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769004120,
      "headline": "Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference",
      "id": 138196024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "SAN DIEGO, January 21, 2026--Biocom today announced a distinguished keynote session for its 2026 Global Partnering & Investor Conference, taking place February 24 to 26 at The Lodge at Torrey Pines in La Jolla, California.",
      "url": "https://finnhub.io/api/news?id=7ded13c7bffe9a1eb7f0ee157151db09457910563196ab72f67489c6c0cd22d7"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in. On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its push into the rapidly growing obesity-treatment market, outlining its plans at the JPMorgan Healthcare Conference. The company’s plans center on GUBamy, an amylin-mimetic weight-loss drug […]",
    "url": "https://finnhub.io/api/news?id=165f92390b70c184bd2bb564d0da2507b936b6be0ef8d05d1a252659a674e8f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768997445,
      "headline": "AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market",
      "id": 138195095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in. On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its push into the rapidly growing obesity-treatment market, outlining its plans at the JPMorgan Healthcare Conference. The company’s plans center on GUBamy, an amylin-mimetic weight-loss drug […]",
      "url": "https://finnhub.io/api/news?id=165f92390b70c184bd2bb564d0da2507b936b6be0ef8d05d1a252659a674e8f6"
    }
  }
]